Switch theme
Sign up to access all valuation multiples
Ubcare Co Ltd is a South Korea based company engages in the provision of healthcare solutions. It provides medical equipment, e-commerce services, and health functional foods online and offline, e-healthcare, mobile healthcare, home healthcare, and other healthcare services.
1992
n/a
Last FY Revenue $139M
Last FY EBITDA $7.3M
$131M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Ubcare achieved revenue of $139M and an EBITDA of $7.3M.
Ubcare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ubcare valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $139M | XXX | XXX | XXX |
| Gross Profit | XXX | $69.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 50% | XXX | XXX | XXX |
| EBITDA | XXX | $7.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 5% | XXX | XXX | XXX |
| EBIT | XXX | $3.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | 3% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.2M | XXX | XXX | XXX |
| Net Margin | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ubcare's stock price is KRW 3770 (or $3).
Ubcare has current market cap of KRW 191B (or $139M), and EV of KRW 180B (or $131M).
See Ubcare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $131M | $139M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ubcare has market cap of $139M and EV of $131M.
Ubcare's trades at 0.9x EV/Revenue multiple, and 17.9x EV/EBITDA.
Equity research analysts estimate Ubcare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ubcare's P/E ratio is not available.
See valuation multiples for Ubcare and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $139M | XXX | $139M | XXX | XXX | XXX |
| EV (current) | $131M | XXX | $131M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 17.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 34.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -120.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -45.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialUbcare's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Ubcare's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ubcare's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ubcare and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ubcare acquired XXX companies to date.
Last acquisition by Ubcare was XXXXXXXX, XXXXX XXXXX XXXXXX . Ubcare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ubcare founded? | Ubcare was founded in 1992. |
| Where is Ubcare headquartered? | Ubcare is headquartered in South Korea. |
| Is Ubcare publicy listed? | Yes, Ubcare is a public company listed on KRX. |
| What is the stock symbol of Ubcare? | Ubcare trades under 032620 ticker. |
| When did Ubcare go public? | Ubcare went public in 1997. |
| Who are competitors of Ubcare? | Similar companies to Ubcare include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of Ubcare? | Ubcare's current market cap is $139M |
| Is Ubcare profitable? | Yes, Ubcare is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
